Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
I find the fact you’ve learned to speak clickbait concerning
Be less concerned, I was going for Bumper Sticker or T-Shirt slogan.